| 000 | 01876 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250515201158.0 | ||
| 264 | 0 | _c20100319 | |
| 008 | 201003s 0 0 eng d | ||
| 022 | _a1528-0020 | ||
| 024 | 7 |
_a10.1182/blood-2009-10-246363 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSantos, Fabio P S | |
| 245 | 0 | 0 |
_aPhase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. _h[electronic resource] |
| 260 |
_bBlood _cFeb 2010 |
||
| 300 |
_a1131-6 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 | _aBlotting, Western |
| 650 | 0 | 4 |
_aCarbazoles _xtherapeutic use |
| 650 | 0 | 4 |
_aCytokines _xmetabolism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFurans |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aJanus Kinase 2 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aPolycythemia Vera _xcomplications |
| 650 | 0 | 4 |
_aPrimary Myelofibrosis _xcomplications |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aProtein-Tyrosine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aThrombocythemia, Essential _xcomplications |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aKantarjian, Hagop M | |
| 700 | 1 | _aJain, Nitin | |
| 700 | 1 | _aManshouri, Taghi | |
| 700 | 1 | _aThomas, Deborah A | |
| 700 | 1 | _aGarcia-Manero, Guillermo | |
| 700 | 1 | _aKennedy, Debra | |
| 700 | 1 | _aEstrov, Zeev | |
| 700 | 1 | _aCortes, Jorge | |
| 700 | 1 | _aVerstovsek, Srdan | |
| 773 | 0 |
_tBlood _gvol. 115 _gno. 6 _gp. 1131-6 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1182/blood-2009-10-246363 _zAvailable from publisher's website |
| 999 |
_c19390226 _d19390226 |
||